Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement.

Autor:	Sahai SK; Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, TX. Electronic address: sksahai@utmb.edu., Balonov K; Department of Anesthesiology and Perioperative Medicine, Tufts University School of Medicine, Boston, MA., Bentov N; Department of Family Medicine, University of Washington, Seattle, WA., Bierle DMM; Division of General Internal Medicine, Mayo Clinic, Rochester, MN., Browning LM; Department of Anesthesia, Parkview Ortho Hospital, Fort Wayne, IN., Cummings KC 3rd; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH., Dougan BM; Division of General Internal Medicine, Mayo Clinic, Rochester, MN., Maxwell M; Department of Anesthesiology and Pain Management, The University of Texas Southwestern Medical Center, Dallas, TX., Merli GJ; Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA., Oprea AD; Department of Anesthesiology, Yale School of Medicine, New Haven, CT., Sweitzer B; University of Virginia School of Medicine, Charlottesville, VAkInova Health Systems, Falls Church, VA; Inova Health Systems, Falls Church, VA., Mauck KF; Division of General Internal Medicine, Mayo Clinic, Rochester, MN., Urman RD; Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jazyk:	angličtina
Zdroj:	Mayo Clinic proceedings [Mayo Clin Proc] 2022 Sep; Vol. 97 (9), pp. 1734-1751.
DOI:	10.1016/j.mayocp.2022.03.039
Abstrakt:	Cardiovascular conditions such as hypertension, arrhythmias, and heart failure are common in patients undergoing anesthesia for surgical or other procedures. Numerous guidelines from various specialty societies offer variable recommendations for the perioperative management of these medications. The Society for Perioperative Assessment and Quality Improvement identified a need to provide multidisciplinary evidence-based recommendations for preoperative medication management. The society convened a group of 13 members with expertise in perioperative medicine and training in anesthesiology or internal medicine. The aim of this consensus effort is to provide perioperative clinicians with guidance on the management of cardiovascular medications commonly encountered during the preoperative evaluation. We used a modified Delphi process to establish consensus. Twenty-one classes of medications were identified: α-adrenergic receptor antagonists, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitors, β-adrenoceptor blockers, calcium-channel blockers, centrally acting sympatholytic medications, direct-acting vasodilators, loop diuretics, thiazide diuretics, potassium-sparing diuretics, endothelin receptor antagonists, cardiac glycosides, nitrodilators, phosphodiesterase-5 inhibitors, class III antiarrhythmic agents, potassium-channel openers, renin inhibitors, class I antiarrhythmic agents, sodium-channel blockers, and sodium glucose cotransportor-2 inhibitors. We provide recommendations for the management of these medications preoperatively. (Copyright © 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu